Stockscreener 앱 받기
5.15
3.20%
-0.17
시간 외 거래:
5.15
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by JPMorgan Chase & Co. - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
This trade activity should not be overlooked: Amylyx Pharmaceuticals Inc (AMLX) - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Investor’s Delight: Amylyx Pharmaceuticals Inc (AMLX) Closes Strong at 5.11, Up 4.29 - DWinneX
Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment - Yahoo Finance
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycem - GuruFocus
Potential Price Increase for Amylyx Pharmaceuticals Inc (AMLX) After Recent Insider Activity - knoxdaily.com
Amylyx Pharmaceuticals Starts Dosing in Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment - marketscreener.com
Amylyx Pharmaceuticals Inc (AMLX) stock: A year of ups and downs - uspostnews.com
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx starts Phase 3 trial for hypoglycemia treatment By Investing.com - Investing.com India
Amylyx starts Phase 3 trial for hypoglycemia treatment - Investing.com
Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia - marketscreener.com
Guggenheim Capital LLC Has $136,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Geode Capital Management LLC Grows Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
AMLX’s Stock Journey: What Investors Need to Know About Amylyx Pharmaceuticals Inc’s Performance - investchronicle.com
Amylyx Pharma Gearing Up For FDA Decision - RTTNews
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Stock Surge: Amylyx Pharmaceuticals Inc (AMLX) Closes at 3.00, Marking a -9.09 Increase/Decrease - DWinneX
What is the investor’s view on Amylyx Pharmaceuticals Inc (AMLX)? - uspostnews.com
Recent Insider Activity Could Benefit Amylyx Pharmaceuticals Inc (AMLX) - knoxdaily.com
Amylyx Pharmaceuticals Inc Shares Are Up 148.48% Since The Beginning Of The Year - Marketing Sentinel
Amylyx Pharmaceuticals Inc (AMLX) Stock: A Year of Market Fluctuations - investchronicle.com
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Q1 Earnings Forecast for AMLX Issued By Leerink Partnrs - Defense World
Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Acquires Shares of 209,708 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx upgraded at Mizuho on potential of lead asset - MSN
First subject dosed in Amylyx’s Phase I trial of ALS therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis - marketscreener.com
Breakthrough ALS Treatment Enters Human Trials: Amylyx Targets New Disease Mechanism - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Is Now The Time To Buy Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Stock? - stocksregister.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Rating Increased to Outperform at Mizuho - Defense World
Mizuho Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx stock upgraded at Mizuho on lead asset (AMLX:NASDAQ) - Seeking Alpha
Mizuho lifts Amylyx stock rating, doubles price target to $7 - Investing.com
0.39%
3.66%
자본화:
|
볼륨(24시간):